Abstract 4041: Interleukin-10 Concentration and Coronary Heart Disease (CHD) Event Risk in the Estrogen Replacement and Atherosclerosis (ERA) Study
Interleukin-10 (IL−10) is a cytokine with both pro- and anti-inflammatory properties. Limited biochemical and clinical evidence suggest a link between IL−10 and coronary heart disease (CHD). However, more data are needed to clarify the relationship between IL−10 and risk for CHD events.
METHODS: The present study was a secondary analysis of the Estrogen Replacement and Atherosclerosis (ERA) trial which was a randomized clinical trial that examined the effects of hormone replacement therapy on post-menopausal women with known coronary atherosclerosis. IL−10 concentration, measured at baseline, was treated as both a continuous and categorical variable. Cox proportional hazards models were used to compute hazard ratios as estimates of relative risk for CHD events.
RESULTS: There were 71 events over an average 3.2 year follow-up. Incident rates were higher for individuals with IL−10 concentrations equal to or greater than the median level (1.04 pg/mL) compared to those individuals below the median level (30% vs. 18.5 %, p=0.02). The cumulative incidence of CHD events was significantly greater in individuals with IL−10 concentrations ≥1.04 pg/mL (p=0.01). A one standard deviation increase in baseline IL−10 concentration was associated with a 34% greater risk of a CHD event (HR 1.34 [1.06–1.68], p=0.01). This elevated risk was not altered by interleukin-6, C-reactive protein, or additional cardiovascular risk factors.
CONCLUSION: Elevated IL−10 concentration was associated with an increased risk for future cardiovascular events in post-menopausal women with established coronary atherosclerosis.